Kimberly B. Dahlman
YOU?
Author Swipe
View article: Core Exchange: A Professional Development Program forShared Resource Personnel
Core Exchange: A Professional Development Program forShared Resource Personnel Open
This model of local shared resource professional development serves as a template for institutions who desire to create opportunities for collaboration and community building. With a small coordinating committee of dedicated individuals, a…
View article: Teaching Biochemistry to Students of Dentistry, Medicine, and Pharmacy 9th International Conference of the Association of Biochemistry Educators (ABE) Kiawah Island, South Carolina, April 30–May 4, 2023
Teaching Biochemistry to Students of Dentistry, Medicine, and Pharmacy 9th International Conference of the Association of Biochemistry Educators (ABE) Kiawah Island, South Carolina, April 30–May 4, 2023 Open
View article: Professional Identity Formation of Basic Science Medical Educators: A Qualitative Study of Identity Supports and Threats
Professional Identity Formation of Basic Science Medical Educators: A Qualitative Study of Identity Supports and Threats Open
Purpose Basic science medical educators (BSME) play a vital role in the training of medical students, yet little is known about the factors that shape their professional identities. This multi-institutional qualitative study investigated f…
View article: Supplementary Figure 7 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 7 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 76K, B-RAFi and MEKi combinatorial treatments lead to strong synergistic growth inhibition of V600EB-RAF cell lines regardless of concurrent P124SMEK1 expression. M229 and M238 vector vs. MEK1 stable cell lines were cultured wit…
View article: Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
PDF file 175K, Catalogue of mechanisms and pathways analyzed and their results
View article: Supplementary Figure Legends 1-11 from <i>BRAF</i><sup>L597</sup> Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Supplementary Figure Legends 1-11 from <i>BRAF</i><sup>L597</sup> Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors Open
PDF file - 57K
View article: Supplementary Figure 1 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 1 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 181K, Patient tissues harboring concurrent and somatic B-RAF and MEK1 mutations. Chromatograms showing B-RAF exon 15 at V600 codon and MEK1 exon 3 at I111 or P124 codons in patient-matched normal tissue, baseline melanomas (prio…
View article: Supplementary Figure 4 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 4 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 76K, Relative expression levels of WT vs. P124SMEK1 in the YUKSI B-RAF/MEK1 double-mutant melanoma short-term culture. Genomic DNA (gDNA) and cDNA derived from YUKSI were subjected to exon 3 sequencing by the Sanger method. Rela…
View article: Supplementary Table S5 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S5 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
XLSX file 12K, Accounting of frequencies of detecting core resistance pathway mechanisms
View article: Supplementary Figure 3 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 3 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 188K, Effects of MEK1 P124S co-expression with B-RAF V600K on cellular p-ERK levels and growth inhibitory sensitivities to B-RAFi and MEKi. (A) The YULAC V600KB-RAF melanoma cell line was stably introduced with the doxycycline-r…
View article: Data from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Data from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance Open
Next generation sequencing (NGS) has been used to characterize the overall genomic landscape of melanomas. Here, we systematically examined mutations from recently published melanoma NGS data involving 241 paired tumor-normal samples to id…
View article: Supplementary Table S3 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S3 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
XLSX file 16K, WES data characteristics including library construction, total reads, base coverage, capture specificity
View article: Supplementary Figure 7 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 7 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 76K, B-RAFi and MEKi combinatorial treatments lead to strong synergistic growth inhibition of V600EB-RAF cell lines regardless of concurrent P124SMEK1 expression. M229 and M238 vector vs. MEK1 stable cell lines were cultured wit…
View article: Supplementary Figure 2 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 2 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 46K, Rapid symptomatic relief in patient 12 treated with GSK2118436/dabrafenib. This patient's right axillary nodal tumor was punch-biopsied at baseline (prior to B-RAFi therapy), showing concurrent B-RAF/MEK1 mutations, and bec…
View article: Data from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Data from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with advanced V600E/KBRAF melanomas. Somatic activating MEK1 mutations are thought to be rare in melanomas, but their potential co…
View article: Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance Open
XLSX - 28K, Supplementary Table S14. Mutations in 12 potential cancer genes in pan-negative melanoma samples.
View article: Data from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Data from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAFV600-mutant melanoma, but acquired drug resistance is almost universal. We sought to identify the core resistance pathways and the exte…
View article: Supplementary Tables 3, 5, 6, 8 from <i>BRAF</i><sup>L597</sup> Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Supplementary Tables 3, 5, 6, 8 from <i>BRAF</i><sup>L597</sup> Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors Open
XLS file - 364K, Figures summarizing the WGS analysis and validation efforts, immunoblots for BRAF L597Q and K601E, sequence confirmation of mutation in patient treated with TAK-733, and spectrum of melanoma mutations determined at Vanderb…
View article: Supplementary Figure 5 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 5 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 144K, Long-term effects of P124SMEK1 expression on population doubling and p-ERK levels. (A) Impact of regulated expression of P124SMEK1 on long-term growth of M238. Stable lines expressing empty vector, FLAG-MEK1 WT or FLAG-MEK…
View article: Supplementary Table S4 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S4 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
XLS file 56K, List of called variants re-sequenced by Sanger, their gene identities, protein sequences, and the primers used for Sanger sequencing
View article: Supplementary Figures 1 through 16 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Supplementary Figures 1 through 16 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance Open
PDF - 912K, Supplementary Figure S1. NRAS mutations in the 69 pan-negative melanoma samples. Supplementary Figure S2. KIT mutations in the 69 pan-negative melanoma samples. Supplementary Figure S3. GNAQ mutations in the 69 pan-negative mel…
View article: Data from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Data from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAFV600-mutant melanoma, but acquired drug resistance is almost universal. We sought to identify the core resistance pathways and the exte…
View article: Supplementary Figures 1-11 from <i>BRAF</i><sup>L597</sup> Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Supplementary Figures 1-11 from <i>BRAF</i><sup>L597</sup> Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors Open
PDF file - 480K
View article: Supplementary Figure 1 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors
Supplementary Figure 1 from Preexisting <i>MEK1</i> Exon 3 Mutations in <sup><i>V600E/K</i></sup><i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors Open
PDF file - 181K, Patient tissues harboring concurrent and somatic B-RAF and MEK1 mutations. Chromatograms showing B-RAF exon 15 at V600 codon and MEK1 exon 3 at I111 or P124 codons in patient-matched normal tissue, baseline melanomas (prio…
View article: Supplementary Tables 1 through 13 and Supplementary Table 15 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Supplementary Tables 1 through 13 and Supplementary Table 15 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance Open
PDF - 160K, Supplementary Table S1. Summary of the six next-generation sequencing (NGS) studies containing 241 paired melanoma tumor/normal samples. Supplementary Table S2. Summary of known driver mutations detected in the 241 melanoma sam…
View article: Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S2 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
PDF file 175K, Catalogue of mechanisms and pathways analyzed and their results
View article: Supplementary Table S1 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Table S1 from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
PDF file 89K, Clinical characteristics of patients and their responses to BRAF inhibitors
View article: Supplementary Figures from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Supplementary Figures from Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Open
PDF file 6308K, This includes all supplementary figures except S2 and contains additional clinical data, sequence and copy number analysis as well as immunohistochemical and functional studies
View article: Supplementary File 1 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Supplementary File 1 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance Open
XLSX - 17K, Supplementary File S1. 632 melanoma candidate genes.
View article: Data from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
Data from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance Open
Next generation sequencing (NGS) has been used to characterize the overall genomic landscape of melanomas. Here, we systematically examined mutations from recently published melanoma NGS data involving 241 paired tumor-normal samples to id…